PASG — Passage BIO, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1787297 ·
Last close
$4.22
Market Cap
$13.58M
52W High
$20.00
52W Low
$3.29
ADV30
17,235
Next earnings
—
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,941,000 -4,719,000 20,793,000 20,160,000 20,743,000
Jun 2026 0 — -10,216,000 -7,821,000 25,175,000 24,155,000 20,719,000
Mar 2026 0 — -8,880,000 -7,559,000 36,462,000 33,336,000 24,710,000
Dec 2025 0 — -10,340,000 -12,983,000 62,281,000 46,303,000 43,526,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-32,645,000
Investing CF
$23,000
Financing CF
$23,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.71
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-724,856,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-34,377,000
Pretax Income TTM
$-33,082,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -43,151,000 -45,522,000 62,281,000 43,526,000 18,755,000 -31,509,000
Dec 2024 0 -65,167,000 -64,767,000 102,412,000 41,151,000 61,261,000 -47,956,000
Dec 2023 0 -102,999,000 -102,062,000 150,545,000 39,262,000 111,283,000 -78,264,000
Dec 2022 0 -135,394,000 -136,125,000 243,549,000 42,183,000 201,366,000 -118,210,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$5,732,000
NetIncome TTM
$-36,112,000
OpCashFlow TTM
—
Assets (Latest)
$25,175,000
Forward EPS
$-11.55

Peers — same industry

TickerNameMarket CapLastDaily %
PLUR Pluri Inc. $14.09M $0.98 —
ESLA Estrella Immunopharma, Inc. $14.42M $0.33 —
DYAI DYADIC INTERNATIONAL INC $12.66M $0.32 —
CKDXF Opthea Ltd $14.64M $0.01 —
ATYR aTYR PHARMA INC $12.47M $4.99 —

News headlines (Yahoo Finance, 1h cache)

Remix to go public in reverse merger with once high-flying Passage Bio
2026-06-25 10:55 · Yahoo
Passage Bio and Remix Therapeutics Announce Merger Agreement
2026-06-24 20:05 · Yahoo
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?
2026-06-24 22:47 · Yahoo
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
2026-04-21 18:20 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-04-21 19:57 · Yahoo
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
2026-04-21 15:46 · Yahoo
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
2026-04-20 11:00 · Yahoo
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
2026-06-25 01:43 · Yahoo
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
2026-05-20 12:35 · Yahoo
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
2026-03-03 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.